Bone Morphogenetic Proteins

Bone Morphogenetic Proteins

Global Bone Morphogenetic Proteins Market to Reach US$715.2 Million by 2030

The global market for Bone Morphogenetic Proteins estimated at US$607.2 Million in the year 2023, is expected to reach US$715.2 Million by 2030, growing at a CAGR of 2.4% over the analysis period 2023-2030. Recombinant human bone morphogenetic protein-2 (rhBMP-2), one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$484.6 Million by the end of the analysis period. Growth in the Recombinant human bone morphogenetic protein-7 (rhBMP-7) segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$163.6 Million While China is Forecast to Grow at 2.1% CAGR

The Bone Morphogenetic Proteins market in the U.S. is estimated at US$163.6 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$112.2 Million by the year 2030 trailing a CAGR of 2.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Bone Morphogenetic Proteins Market - Key Trends & Drivers Summarized

Why Are Bone Morphogenetic Proteins Gaining Popularity in Orthopedic Surgeries?

Bone morphogenetic proteins (BMPs) have emerged as a critical component in orthopedic surgeries, particularly for their ability to promote bone growth and healing. BMPs are used in spinal fusions, bone defects, and fracture treatments where traditional healing is slow or difficult. Their ability to induce osteogenesis (bone formation) has made them indispensable in cases requiring bone regeneration, such as in complex fractures or after tumor resections. As the global incidence of musculoskeletal disorders and injuries rises, the demand for BMPs in surgical procedures has grown, making them a popular choice for enhancing patient recovery outcomes.

How Are Technological Innovations Improving the Application of Bone Morphogenetic Proteins?

Technological advancements are playing a key role in improving the efficacy and delivery of bone morphogenetic proteins. New methods of BMP delivery, such as biodegradable scaffolds and nanotechnology-based carriers, are being developed to target the precise location of bone defects, thereby optimizing the therapeutic effects while reducing potential side effects. Furthermore, innovations in recombinant DNA technology have allowed for the production of synthetic BMPs, which are now widely available for clinical use. These developments have expanded the use of BMPs beyond traditional orthopedic surgeries, making them suitable for dental, craniofacial, and even cardiovascular applications.

What Impact Does the Growing Prevalence of Osteoporosis and Fractures Have on BMP Demand?

The rising prevalence of osteoporosis and the increasing number of bone fractures, particularly among the aging population, are key drivers of demand for bone morphogenetic proteins. Osteoporosis, a condition characterized by weakened bones, leads to an increased risk of fractures, especially in older adults. BMPs offer a solution to improve bone regeneration and healing in these patients, where natural recovery might be impaired. With healthcare providers focused on improving patient outcomes and reducing recovery times, BMPs are becoming an essential tool in the treatment of fractures, spinal fusions, and bone defects caused by degenerative diseases or trauma.

The Growth in the Bone Morphogenetic Proteins Market Is Driven by Several Factors

The growth in the bone morphogenetic proteins market is driven by several factors, including increasing surgical procedures for orthopedic injuries, advancements in biotechnology, and the rising prevalence of bone-related disorders such as osteoporosis. The aging population is a significant factor, as older adults are more prone to fractures and bone degeneration, driving the need for bone regenerative therapies. Technological innovations in BMP delivery systems, including targeted delivery mechanisms and synthetic production techniques, are also boosting market growth. Additionally, the expanding use of BMPs in non-orthopedic areas, such as dental and craniofacial surgeries, is further broadening the scope of their application, contributing to the market’s rapid expansion.

Select Competitors (Total 53 Featured) -

• Cellumed Co. Ltd
• DePuy Synthes
• Ember Therapeutics
• Medtronic
• Musculoskeletal Transplant Foundation
• Nuvasive, Inc
• Orthofix Holdings, Inc
• ProSpec-Tany TechnoGene Ltd
• Sigma-Aldrich Co
• Smith and Nephew, Inc
• Stryker Corporation
• Wright Medical Group N.V.
• Xtant Medical Holdings, Inc
• Zimmer Biomet Holdings, Inc

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.